34 results match your criteria: "Avinguda de La Granvia de L'Hospitalet[Affiliation]"

Identifying environmental risk factors for inflammatory bowel diseases: a Mendelian randomization study.

Sci Rep

November 2020

Colorectal Cancer Group, ONCOBELL Program, Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Avinguda de La Granvia de L'Hospitalet, 199, 08908, Barcelona, Spain.

Several studies have examined environmental factors and inflammatory bowel diseases (IBD) using traditional approaches; however, provided results are still conflicting. Our aim was to determine whether lifestyle and nutrient exposures, related to IBD in observational meta-analyses, influence IBD risk using a Mendelian randomization (MR) approach. A two-sample MR approach was applied on summary-level genome-wide association results.

View Article and Find Full Text PDF

Colorectal cancer (CRC) is a biologically heterogeneous disease. To characterize its mutational profile, we conduct targeted sequencing of 205 genes for 2,105 CRC cases with survival data. Our data shows several findings in addition to enhancing the existing knowledge of CRC.

View Article and Find Full Text PDF

Alu repeats constitute a major fraction of human genome and for a small subset of them a role in gene regulation has been described. The number of studies focused on the functional characterization of particular Alu elements is very limited. Most Alu elements are DNA methylated and then assumed to lie in repressed chromatin domains.

View Article and Find Full Text PDF

HPV vaccination: Are we overlooking additional opportunities to control HPV infection and transmission?

Int J Infect Dis

November 2019

Cancer Epidemiology Research Programme (CERP), Catalan Institute of Oncology (ICO- IDIBELL), Avinguda de la Granvia de l'Hospitalet 199-203, 08908 L'Hospitalet de Llobregat, Barcelona, Spain; Open University of Catalonia (UOC), Barcelona, Spain.

Human papillomavirus virus-like particles (HPV VLPs) have distinctive immunogenic properties that generate a durable antibody response, producing high-quality neutralizing antibodies. By vaccination, i.e.

View Article and Find Full Text PDF

Risk of breast cancer and residential proximity to industrial installations: New findings from a multicase-control study (MCC-Spain).

Environ Pollut

June 2018

Cancer and Environmental Epidemiology Unit, National Center for Epidemiology, Carlos III Institute of Health, Avda. Monforte de Lemos 5, 28029, Madrid, Spain; Consortium for Biomedical Research in Epidemiology & Public Health (CIBER Epidemiología y Salud Pública - CIBERESP), Avda. Monforte de Lemos 3-5, Madrid, Spain. Electronic address:

Breast cancer is the most frequent tumor in women worldwide, although well-established risk factors account for 53%-55% of cases. Therefore, other risk factors, including environmental exposures, may explain the remaining variation. Our objective was to assess the relationship between risk of breast cancer and residential proximity to industries, according to categories of industrial groups and specific pollutants released, in the context of a population-based multicase-control study of incident cancer carried out in Spain (MCC-Spain).

View Article and Find Full Text PDF

Summary statement on screening for prostate cancer in Europe.

Int J Cancer

February 2018

Department of Public Health, Erasmus Medical Center, Wytemaweg 80, CN Rotterdam, 3015, The Netherlands.

The European Randomised Study of Screening for Prostate Cancer (ERSPC) showed that Prostate-Specific Antigen (PSA) based screening results in a significant prostate cancer mortality reduction. Although there are concerns on overdiagnosis and overtreatment, it has been shown that the benefits can outweigh the harms if screening is stopped in older ages to prevent overdiagnosis. A limited screening program (for example screening at ages 55-59 years), including active surveillance for men with low-risk tumors, can even be cost-saving, compared with testing in an opportunistic setting in the wrong ages, as currently in Europe.

View Article and Find Full Text PDF

Helicobacter pylori serological biomarkers of gastric cancer risk in the MCC-Spain case-control Study.

Cancer Epidemiol

October 2017

Environmental and Cancer Epidemiology Area, National Center of Epidemiology, Carlos III Health Institute (ISCIII), Avda. Monforte de Lemos 5, 28029, Madrid, Spain; Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP)-CIBER of Epidemiology and Public Health (CIBERESP), Avda. Monforte de Lemos, 3-5, Pabellón 11, Planta 0, 28029, Madrid, Spain.

Background: Helicobacter pylori infection is one of the main risk factors for non-cardia gastric cancer. However, only a minority of infected persons develop the disease. This study aims at identifying H.

View Article and Find Full Text PDF

Gastrointestinal stromal sarcomas (GISTs) are the most common mesenchymal tumours originating in the digestive tract. They have a characteristic morphology, are generally positive for CD117 (c-kit) and are primarily caused by activating mutations in the KIT or PDGFRA genes(1). On rare occasions, they occur in extravisceral locations such as the omentum, mesentery, pelvis and retroperitoneum.

View Article and Find Full Text PDF

Residual neck disease management in squamous-cell carcinoma of the head and neck treated with radiotherapy plus cetuximab.

Clin Transl Oncol

November 2016

Medical Oncology Department, Institut Català Oncologia, Avinguda de la Granvia de l'Hospitalet, 199-203, 08908, Hospitalet de Llobregat, Spain.

Purpose: Management of residual neck disease (RND) is one of the unsolved points after bio-radiotherapy (BRT) in loco-regional advanced squamous-cell carcinoma of the head and neck (SCCHN). The aims of the study were to characterize the radiological pattern of response by computed tomography (CT) and to assess the role of positron-emission tomography (PET)/CT in this setting for a better decision-making in the indication of neck dissection (ND).

Methods: We retrospectively reviewed 202 patients consecutively diagnosed with node-positive SCCHN (N1: 24; N2: 152; N3: 26) who had been treated with concomitant radiotherapy and cetuximab with or without previous induction chemotherapy between 2006 and 2013.

View Article and Find Full Text PDF